In 2011 this blog was listed as one of the top 10 blog in pharma technical information it is popular amongst the pharmacists and pharma industry professionals. We have published very important and very useful information for pharma industry professionals.

Friday, January 7, 2022

COVID-19 Treatment Guidelines by National Institute of Health(NIH) USA for Omicron (B.1.1.529) varient infection managmet

The National Institute of Health of the United States has published a guideline for providing Treatment for COVID 19, due to the increased number of Omicron (B.1.1.529) Variants of concern.

The guideline is an eye opener, when NIH mentioned in it that the recently developed monoclonal antibodies treatment for treatment of SARS-COV-2 may not be effective against the Omicron (B.1.1.529).Therefore it has advised in its guideline that doctors should also give remdesavir intravenous dosage to out patients.as well, the use of remedisavir was limited to hospitalized patients, while NIH recommend to make use of the remedisavir in outpatient as well along with NIH in its guideline has also recommended use of only one monoclonal antibody Sotrovimab 500 mg Intravenous as a single infusion (AIIa) immediately within 10 days of symptoms onset.

1.Sotrovimab 500 mg Intravenous as a single infusion (AIIa) immediately and within 10 days of symptom onset .
2. Remdesivir 200 mg intravenous on day 1, then 100 mg once daily on Days 2 and 3 (BIIa) initiated as soon as possible and within 7 days of symptom onset.
Remedesivir intravenous injection requires for three consecutive days therefore it's one of the concerns for outpatients. 
Due to the greater variation in spike protein due to variation in gene sequence the antibodies which were developed with earlier sequence viz bamlanivimab plus etesevimab and casirivimab plus imdevimab, may not be effective against the Omicron (B.1.1.529). Therefore if at all someone makes use of them, it should be kept in mind that they may not work.
Remdesivir is a nucleotide prodrug of an adenosine analog which inhibits the intake of adenosine base by viral RNA during the replication process of SARS COV-2 virus.
Sotrovimab  is a Monoclonal antibody.
Reference : National Institute of Health guidance for Omicron varient treatment approach.

 

No comments:


What is 21 CFR Part 11, US FDA guidelines requirements of FDA compliance and CFR 21 Part 11.

What is a Site Master file of a pharmaceutical company

What is Generic Drug

What is Reference Listed Drug  ? ( RLD )

What is Pharmaceutical Equivalents

What is Pharmaceutical Alternatives

What is Therapeutic Equivalents

What are Post Market studies

Why a drug is bound to protein, What is protein binding?  What is drug absorption , distribution ?

Do Physical properties contribute to drug activity.

What is drug receptor , How a drug resistance occurs

Mechanism of drug resistance

What is drug interaction

Drug interaction, and its examples

What is first pass metabolism of a drug

What is What is 510(k) Clearances ?

What is 510(k) Clearances,

Premarket Notification for medical devices - PMN or 510(k)

What is a drug interaction

Examples of drug interactions


Antibiotic Definition and classification


Antibiotic Resistance and Antibiotic resistance mechanism

Antioxidants food supplements

Vitamin D Details on FDA cautions on accurate dosage of Vitamin D


What is an antibody? what is monoclonal and polyclonal antibodies?

Terminologies In vaccine Production

Multi stage testing of Virus vaccine production

Testing of vaccines at different stages of production

TESTING FOR ADVENTITIOUS AGENTS CELL PROPERTIES IN VIRAL VACCINE PRODUCTION

Enzyme linked immunosorbent assay ELISA

Raido Immuno assay

http://whoguideline.blogspot.com/2010/04/terminalogy-and-their-explanations.html

Pharmaceutical Aseptic Manufacturing Process Terms , Terminology and Definitions.

http://whoguideline.blogspot.com/2010/02/pharmaceutical-aseptic-manufacturing.html

Here are some articles which will be useful for you in further understanding of aspects of sterile dosage form manufacturing and regulatory affairs and good manufacturing practice in

pharmaceutical industry

Pharmaceutical Validation

Types of validations in pharmaceutical manufacturing


Requirements of documents for validation of sterilisation process

How to investigate OOS out of specification results

Determination of Phenol coefficient of a disinfectant

Sterility testing

Clean Room Classification

Time limitations in sterile pharmaceuticals processing

Aspects of validation of manufacturing process in sterile pharmaceuticals

Clinical Trials

Requirements of US FDA Inspections of Clinical Investigators of Clinical Trials

PROCEDURE OF AN INSPECTIONS OF CLINICAL TRIAL INVESTIGATOR BY US FDA HOW ARE CLINICAL INVESTIGATOR INSPECTIONS CONDUCTED?

US FDA INSPECTION OF CLINICAL INVESTIGATORS OUT OF UNITED STATES OF AMERICA

REPORTS AFTER AN INSPECTION OF A INVESTIGAOTR OF CLINICAL TRIALS

Controlling Pyrogens in injectable dosage forms

Media fill run process simulation aspects Validation of Aseptic Process and Sterilisation

New Drug Application (NDA) how to make a New Drug Application (NDA) to US FDA

Abbreviated New Drug Application (ANDA) What is ANDA , detailed information about ANDA preparation and submission to US FDA

How to make Investigational New Drug (IND) Application to US FDA

Drug applications submission to us fda Over the counter Drugs OTC drugs

BIOAVAILABILITY AND BIOEQUIVALENCE REQUIREMENTS

Electronic record in pharmaceutical manufacturing industry

Good manufacturing practice in pharmaceutical industry

Pharmaceutical industry pharmaceutical companies and FDA latest updates